Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor ‐containing regimen

ConclusionsThe addition of RBV to 12 weeks of LDV/SOF has little therapeutic benefit when retreating patients in whom a prior NS5A inhibitor‐containing regimen had failed.

Source: Hepatology Research - March 1, 2018 Category: Internal Medicine Authors: Hiroki Ikeda, Tsunamasa Watanabe, Hirohito Shimizu, Tetsuya Hiraishi, Rena Kaneko, Toshiyuki Baba, Hideaki Takahashi, Kotaro Matsunaga, Nobuyuki Matsumoto, Hiroshi Yasuda, Chiaki Okuse, Shogo Iwabuchi, Michihiro Suzuki, Fumio Itoh Tags: Original Article Source Type: research